Qualitative Interviews on the Experience of Orally vs. Intramuscularly Administered Endocrine Therapy for Advanced Breast Cancer: Patient and Healthcare Provider Perspectives
Patients with ER+ HER2- ABC in this study preferred oral to IM ET owing to convenience, and disliked the pain associated with IM ET and travel to receive injections. Compared to IM fulvestrant, oral SERDs may offer an alternative with less burden on the lives of people living with cancer.
Authors
- Christine Agius (ORCID: https://orcid.org/0000-0001-7023-2155)
- Aarti Chawla
- Elizabeth D. Bacci
- Shakeela Bahadur
- Gale Harding
- Kathryn Elizabeth Hudson (ORCID: https://orcid.org/0000-0002-4974-4428)
- Mohammed Jaloudi
- Rebecca M. Speck (ORCID: https://orcid.org/0000-0002-3580-117X)
- Gregory A. Vidal (ORCID: https://orcid.org/0000-0003-3325-6224)
- Ritesh Parajuli
Institutions
- Brigham and Women's Hospital (US)
- Eli Lilly (United States) (US)
- University of California, Irvine (US)
- Texas Oncology (US)
- West Cancer Center (US)
- Scripps Clinic Medical Group (US)
- Dana-Farber Cancer Institute (US)
- Mayo Clinic Hospital (US)
- Thermo Fisher Scientific (United States) (US)
- Dana-Farber Brigham Cancer Center (US)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1007/s40487-025-00408-5
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00